台灣臨床試驗主持人資料庫|TPIDB

2015-08-17 - 2018-02-28

Phase III

A Randomized, Double-Blind, Double-Dummy, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 10 or 20 mg Compared to Lansoprazole 15 mg in the Maintenance Treatment of Subjects With Endoscopic Healing of Erosive Esophagitis

Condition/Disease

Erosive Esophagitis
Test Drug

TAK-438

Participate Sites
14Sites

Terminated12Sites

邱正堂

Linkou Chang Gung Medical Foundation

Digestive System Department

吳登強

Kaohsiung Municipal Gangshan Hospital

未分科

2015-08-01 - 2017-12-31

Phase I

Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study To evaluate The Safety, Tolerability, And Immunogenicity Of INO-1800 Alone Or in Combination With INO-9112 Delivered IM Followed By Electroporation In Select Nucleos(t)ide Analogue-Treated, HBeAG-Positive, Chronic Hepatitis B Patients

Condition/Disease

Chronic Hepatitis B
Test Drug

INO-1800 and INO-9112

Participate Sites
6Sites

Terminated5Sites

黃怡翔

Taipei Veterans General Hospital

Digestive System Department

莊萬龍

Kaohsiung Municipal Gangshan Hospital

未分科

2016-05-04 - 2020-10-31

Phase II

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT TRIAL OF AC-201 CONTROLLED RELEASE TABLETS IN SUBJECTS WITH HEMOPHILIC ARTHROPATHY

Condition/Disease

HEMOPHILIC ARTHROPATHY
Test Drug

AC-201CR

Participate Sites
6Sites

Terminated5Sites

張家堯

Taipei Medical University Hospital

Division of Hematology & Oncology

邱世欣

Kaohsiung Municipal Gangshan Hospital

未分科

2017-06-01 - 2019-12-31

Phase III

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

Condition/Disease

Alzheimer's Disease
Test Drug

Elenbecestat (E2609)

Participate Sites
13Sites

Terminated11Sites

胡朝榮

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Neurology

劉景寬

Kaohsiung Municipal Gangshan Hospital

未分科

2017-02-01 - 2027-02-01

Phase III

PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

Condition/Disease

Hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Test Drug

Ibrance

Participate Sites
6Sites

Terminated5Sites

曾令民

Taipei Veterans General Hospital

Division of General Surgery

侯明鋒

Kaohsiung Municipal Gangshan Hospital

未分科

Search Result

List